4.8 Article

Notch3 Pathway Alterations in Ovarian Cancer

期刊

CANCER RESEARCH
卷 74, 期 12, 页码 3282-3293

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-13-2066

关键词

-

类别

资金

  1. NIH [P50 CA083639, CA109298, P50 CA098258, UH2 TR000943, CA128797, RO1 CA177909, U54 CA151668]
  2. Ovarian Cancer Research Fund
  3. United States Department of Defense [OC120547, OC093146]
  4. Zarrow Foundation
  5. Marcus Foundation
  6. Chapman Foundation
  7. Meyer and Ida Gordon Foundation
  8. Betty Anne Asche Murray Distinguished Professorship
  9. MD Anderson Cancer Center [CA016672]
  10. Gilder Foundation
  11. RGK Foundation
  12. National Cancer Institute/United States Department of Health and Human Services/NIH [T32 CA101642]
  13. Gynecologic Cancer Foundation/Florence and Marshall Schwid Ovarian Cancer Award

向作者/读者索取更多资源

The Notch pathway plays an important role in the growth of high-grade serous ovarian (HGS-OvCa) and other cancers, but its clinical and biologic mechanisms are not well understood. Here, we found that the Notch pathway alterations are prevalent and significantly related to poor clinical outcome in patients with ovarian cancer. Particularly, Notch3 alterations, including amplification and upregulation, were highly associated with poor patient survival. Targeting Notch3 inhibited ovarian cancer growth and induced apoptosis. Importantly, we found that dynamin-mediated endocytosis was required for selectively activating Jagged-1-mediated Notch3 signaling. Cleaved Notch3 expression was the critical determinant of response to Notch-targeted therapy. Collectively, these data identify previously unknown mechanisms underlying Notch3 signaling and identify new, biomarker-driven approaches for therapy. (C)2014 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据